As a combination therapy, IL12 has been used as an adjuvant to enhance cytotoxic immunity using a melanoma antigen vaccine [71] or using peptide-pulsed peripheral blood mononuclear cells [72] and to promote NK-cell mediated killing of HER2-positive breast cancer cells in patients treated with trastuzumab [73]. This evidence concerns the gene ERBB2 and breast cancer.